IRTC:NSD-iRhythm Technologies Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 141.10

Change

0.00 (0.00)%

Market Cap

USD 4.15B

Volume

0.44M

Avg Analyst Target

USD 132.47 (-6.12%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


iRhythm Technologies Inc (IRTC) Stock Analysis:
Based on the iRhythm Technologies Inc stock forecasts from 8 analysts, the average analyst target price for iRhythm Technologies Inc is USD 132.47 over the next 12 months. iRhythm Technologies Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of iRhythm Technologies Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, iRhythm Technologies Inc’s stock price was USD 141.10. iRhythm Technologies Inc’s stock price has changed by +11.06% over the past week, +34.23% over the past month and -43.69% over the last year.

About

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-b ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

N/A

USD43.36B 84.37 117.62
ALGN Align Technology Inc

N/A

USD41.37B 56.55 48.05
PODD Insulet Corporation

N/A

USD16.74B 2,208.27 199.97
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed Inc

N/A

USD13.70B 92.48 46.15
BRKR Bruker Corporation

N/A

USD10.73B 39.93 25.78
TNDM Tandem Diabetes Care Inc

N/A

USD7.67B 356.22 187.52
SWAV ShockWave Medical Inc

N/A

USD5.90B N/A N/A
IART Integra LifeSciences Holdings ..

N/A

USD5.83B 27.08 17.89
LIVN LivaNova PLC

N/A

USD4.51B 77.40 N/A

ETFs Containing IRTC

Symbol Name Weight Mer Price(Change) Market Cap
ROBO Robo Global Robotics and .. 0.00 % 0.95 %

N/A

USD1.96B
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B
ROBO Robo Global Robotics and .. 0.00 % 0.95 %

N/A

USD1.96B
HTEC Robo Global Healthcare Te.. 0.00 % 0.68 %

N/A

USD0.22B
ROBE:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

USD1.30B
ROBG:LSE Legal & General UCITS ETF.. 0.00 % 0.80 %

+15.75 (+0.82%)

USD1.30B
ROBO:LSE Legal & General UCITS ETF.. 0.00 % 0.80 %

+0.17 (+0.65%)

USD1.30B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.59 %

N/A

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.89% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.89% 98% A+ 98% A+
Trailing 12 Months  
Capital Gain -43.69% 36% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.69% 36% F 24% F
Trailing 5 Years  
Capital Gain 379.77% 91% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 379.77% 91% A- 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 43.86% 71% C- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.86% 71% C- 83% B
Risk Return Profile  
Volatility (Standard Deviation) 82.00% 35% F 20% F
Risk Adjusted Return 53.48% 78% C+ 73% C
Market Capitalization 4.15B 91% A- 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.96 22% F 13% F
Price / Cash Flow Ratio -301.77 96% A 95% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -24.91% 51% F 37% F
Return on Invested Capital -16.11% 55% F 30% F
Return on Assets -9.89% 54% F 29% F
Debt to Equity Ratio 6.25% 71% C- 76% C
Technical Ratios  
Short Ratio 2.24 59% F 51% F
Short Percent 3.85% 44% F 40% F
Beta 1.19 45% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector